Innerwell operates a psychedelic teletherapy platform that provides ketamine-assisted psychotherapy through a remote care model. The service connects patients with licensed clinicians to support treatment for depression, anxiety, and PTSD in a supervised, at-home setting.

The team believes the market for mental health treatment is ripe for innovation, particularly in actual treatments beyond just access. They see significant potential in novel molecules like ketamine, MDMA, and psilocybin, and Innerwell's infrastructure is adaptable to these evolving treatments. Innerwell offers a "one-stop shop" for behavioral health, integrating licensed clinicians, therapists, and care coordinators, which is seen as unique among competitors. Furthermore, their emphasis on a data layer, collecting and utilizing patient data for clinical care optimization and personalized recommendations, is considered a key differentiator and a valuable asset.